These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16789621)

  • 1. Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome.
    Lala R; Matarazzo P; Andreo M; Marzari D; Bellone J; Corrias A; de Sanctis C;
    J Pediatr Endocrinol Metab; 2006 May; 19 Suppl 2():583-93. PubMed ID: 16789621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
    Lala R; Matarazzo P; Bertelloni S; Buzi F; Rigon F; de Sanctis C
    Acta Paediatr; 2000 Feb; 89(2):188-93. PubMed ID: 10709889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
    Matarazzo P; Lala R; Masi G; Andreo M; Altare F; de Sanctis C
    J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():929-37. PubMed ID: 12199352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood.
    Chan B; Zacharin M
    J Pediatr Endocrinol Metab; 2006 Jan; 19(1):75-80. PubMed ID: 16509531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia.
    Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA
    J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate therapy for fibrous dysplasia.
    DiMeglio LA
    Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():440-5. PubMed ID: 17982393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pamidronate for fibrous dysplasia due to McCune Albright Syndrome.
    Kochar IP; Kulkarni KP
    Indian Pediatr; 2010 Jul; 47(7):633-5. PubMed ID: 20683120
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome.
    Zacharin M; O'Sullivan M
    J Pediatr; 2000 Sep; 137(3):403-9. PubMed ID: 10969268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].
    Pfeilschifter J; Ziegler R
    Med Klin (Munich); 1998 Jun; 93(6):352-9. PubMed ID: 9662942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent femur neck fracture and response to bisphosphonates in polyostotic fibrous dysplasia.
    Rastogi A; Bhadada SK; Bhansali A
    Indian J Pediatr; 2012 May; 79(5):667-9. PubMed ID: 21761121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia.
    Isaia GC; Lala R; Defilippi C; Matarazzo P; Andreo M; Roggia C; Priolo G; de Sanctis C
    Calcif Tissue Int; 2002 Aug; 71(2):121-8. PubMed ID: 12200645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of antiresorptive agents in fibrous dysplasia and McCune Albright syndrome, a systematic review and meta-analysis.
    Bertin H; Moussa MS; Komarova S
    Rev Endocr Metab Disord; 2023 Dec; 24(6):1103-1119. PubMed ID: 37632645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab in Patients With Fibrous Dysplasia Previously Treated With Bisphosphonates.
    Majoor BCJ; Papapoulos SE; Dijkstra PDS; Fiocco M; Hamdy NAT; Appelman-Dijkstra NM
    J Clin Endocrinol Metab; 2019 Dec; 104(12):6069-6078. PubMed ID: 31390018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
    Wang Y; Wang O; Jiang Y; Li M; Xia W; Meng X; Xing X
    Endocr Pract; 2019 Jan; 25(1):23-30. PubMed ID: 30383490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.
    Plotkin H; Rauch F; Zeitlin L; Munns C; Travers R; Glorieux FH
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4569-75. PubMed ID: 14557424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia/McCune-Albright syndrome.
    Meier ME; Hagelstein-Rotman M; Streefland TCM; Winter EM; Bravenboer N; Appelman-Dijkstra NM
    Bone; 2023 Jun; 171():116744. PubMed ID: 36958543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrous dysplasia & McCune-Albright syndrome: an experience from a tertiary care centre in north India.
    Bhadada SK; Bhansali A; Das S; Singh R; Sen R; Agarwal A; Mittal BR; Nahar U; Dutta P; Khandelwal N
    Indian J Med Res; 2011 May; 133(5):504-9. PubMed ID: 21623035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eight-year follow-up of a girl with McCune-Albright syndrome.
    Aycan Z; Önder A; Çetinkaya S
    J Clin Res Pediatr Endocrinol; 2011; 3(1):40-2. PubMed ID: 21448334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scoliosis in Fibrous Dysplasia/McCune-Albright Syndrome: Factors Associated With Curve Progression and Effects of Bisphosphonates.
    Berglund JA; Tella SH; Tuthill KF; Kim L; Guthrie LC; Paul SM; Stanton R; Collins MT; Boyce AM
    J Bone Miner Res; 2018 Sep; 33(9):1641-1648. PubMed ID: 29669167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study.
    Meier ME; Clerkx SN; Winter EM; Pereira AM; van de Ven AC; van de Sande MAJ; Appelman-Dijkstra NM
    J Bone Miner Res; 2021 Sep; 36(9):1729-1738. PubMed ID: 34076303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.